Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shusuke Akamatsu

Showing results (51-60 of 216) with videos related to

Pageof 22
Sort By:
International Journal of Clinical Oncology|June 2, 2019
Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivationRihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
International Journal of Clinical Oncology|December 11, 2019
Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapyRihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
Urologic Oncology|October 31, 2020
Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancerRihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
The Pharmacogenomics Journal|March 2, 2021
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancerMasaki Shiota, Shusuke Akamatsu, Shintaro Narita, et al.
Journal of Molecular Endocrinology|April 24, 2019
PEG10 is associated with treatment-induced neuroendocrine prostate cancerSoojin Kim, Daksh Thaper, Samir Bidnur, et al.
Frontiers in Immunology|July 22, 2022
Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint BlockadeMasashi Takeda, Soki Kashima, Yasushi Fuchigami, et al.
IJU Case Reports|September 12, 2022
Paraurachal paragangliomaMasafumi Tsuruta, Takayuki Goto, Jin Kono, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 28, 2025
Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignanciesTakaya Suzuki, Kazuyuki Mizuno, Takafumi Yamamoto, et al.
International Journal of Clinical Oncology|June 29, 2016
Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional studyNaoki Terada, Shusuke Akamatsu, Yoshiyuki Okada, et al.
JAMA Network Open|February 23, 2019
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneMasaki Shiota, Shintaro Narita, Shusuke Akamatsu, et al.
Pageof 22

Showing results (51-60 of 216) with videos related to

Sort By:
Pageof 22
International Journal of Clinical Oncology|June 2, 2019
Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivationRihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
International Journal of Clinical Oncology|December 11, 2019
Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapyRihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
Urologic Oncology|October 31, 2020
Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancerRihito Aizawa, Kenji Takayama, Kiyonao Nakamura, et al.
The Pharmacogenomics Journal|March 2, 2021
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancerMasaki Shiota, Shusuke Akamatsu, Shintaro Narita, et al.
Journal of Molecular Endocrinology|April 24, 2019
PEG10 is associated with treatment-induced neuroendocrine prostate cancerSoojin Kim, Daksh Thaper, Samir Bidnur, et al.
Frontiers in Immunology|July 22, 2022
Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint BlockadeMasashi Takeda, Soki Kashima, Yasushi Fuchigami, et al.
IJU Case Reports|September 12, 2022
Paraurachal paragangliomaMasafumi Tsuruta, Takayuki Goto, Jin Kono, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 28, 2025
Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignanciesTakaya Suzuki, Kazuyuki Mizuno, Takafumi Yamamoto, et al.
International Journal of Clinical Oncology|June 29, 2016
Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional studyNaoki Terada, Shusuke Akamatsu, Yoshiyuki Okada, et al.
JAMA Network Open|February 23, 2019
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneMasaki Shiota, Shintaro Narita, Shusuke Akamatsu, et al.
Pageof 22